-
Lepu Biologics TF ADC submits a clinical application for new drugs in China
Time of Update: 2021-07-06
On June 7, the new drug clinical trial application (IND) of the antibody-conjugated drug MRG004A that targets tissue factor (TF) submitted by Shanghai Miac, a wholly-owned subsidiary of Lepu Bio, was accepted by CDE .
-
New double-anti-ADC and ADC players enter the game, and financing companies "challenge" leading position in May
Time of Update: 2021-07-06
Based on the three major medical R&D technology platforms of ElpisourceTM, a new target discovery platform, ImmunosineTM, an in vitro drug efficacy screening platform for tumor immunity, and AbLegoTM, a double-antibody design platform, Kewang Pharmaceutical’s R&D pipeline covers a wide range of tumor immunity and is in the field of natural immunity with great potential.
-
"Keji Pharmaceutical" broke the market?
Time of Update: 2021-07-06
Like most innovative pharmaceutical companies, Keji Pharmaceuticals also strongly recommends itself in the prospectus, calling itself "the leader in the field of CAR-T cell therapy", and stated that it is the world's first to successfully identify, verify and report Claudin18.
-
The China Securities Regulatory Commission agrees to the IPO registration of Beike Biotech Innovation Board
Time of Update: 2021-07-06
Today, Changchun High-tech issued an announcement stating that the company’s subsidiary Beike Biotechnology has received the "Approval to the Registration of the Initial Public Offering of Changchun Beike Biotechnology Co.
1594), the China Securities Regulatory Commission approved the registration application for the initial public offering of Baike Biotech .
-
Over 1.3 billion US dollars! Biogen and Capsigen collaborate to develop gene therapy
Time of Update: 2021-07-06
Biogen and Capsigen recently announced that the two companies have signed a strategic research cooperation agreement to design a new type of adeno-associated virus capsids (AAVcapsids) with the potential to deliver transformative gene therapies to address a variety of central nervous systems and nerves.
-
Jixing Pharmaceutical Co., Ltd. over 100 million US dollars introduces tachycardia nasal administration therapy
Time of Update: 2021-07-06
On May 17, Milestone Pharmaceuticals, an innovative cardiovascular drug research and development company, announced that it has reached an exclusive license and cooperation agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil for paroxysmal rooms in Greater China.
-
Genetron Health and JD Health start strategic cooperation
Time of Update: 2021-07-06
Relying on HCCscreenTM, a liquid biopsy product for early screening of liver cancer, and a combined detection kit for human 8 gene mutations, Genetron Health cooperates with JD Health to cover early cancer screening, molecular typing, medication guidance, and drug resistance monitoring to provide a wider range of users with more precision and efficiency , More accessible cancer full-cycle management services .
-
Postpone the approval of anti-cancer drugs!
Time of Update: 2021-07-06
However, former Xinji shareholders stated that one of the new CAR-T drugs, liso-cel, for the treatment of non-Hodgkin’s lymphoma, had not been approved by the FDA before December 31 last year, and the payment had disappeared out of thin air.
-
Kanghong Pharmaceutical's Conbercept ophthalmic injection was approved for clinical use
Time of Update: 2021-07-06
On the 4th, Kanghong Pharmaceutical issued an announcement stating that its wholly-owned subsidiary had recently received the "Drug Clinical Trial Approval Notice" for Conbercept ophthalmic injection issued by the State Food and Drug Administration, and agreed to carry out clinical trials .
Approved in 2019 for the treatment of visual impairment secondary to diabetic macular edema (DME) .
-
Tianjing Bio announced the completion of the first patient's administration in the Chinese study of the combination of TJC4 and azacitidine
Time of Update: 2021-07-06
The recruitment of NHL and advanced solid tumor patients is expected to be completed in the fourth quarter of 2021, and the preliminary results of the clinical study will be announced at a follow-up academic conference .
-
Huadong Medicine metformin and Enpagliflozin tablets (I) obtained the drug registration certificate
Time of Update: 2021-07-06
On the 8th, Huadong Medicine announced that its wholly-owned subsidiary, Zhongmei Huadong, received the approval of the State Food and Drug Administration for the issuance of the "Drug Registration Certificate" for metformin and enpagliflozin tablets (I) .
-
NKN Lab and Wolfram Research jointly hold a distributed consensus online science seminar
Time of Update: 2021-07-06
In this scientific seminar, we specially invited Wolfram Stephen, the founder of Wolfram Research, the author of "A New Science", and the official technical consultant of NKN as the guest speakers to share distributed consensus, cellular automata and other related systems .
-
Shenzhen Haipurui donated international pilot production lines to help Shenzhen pharmaceutical innovation
Time of Update: 2021-07-06
("Tiandao"), donated a well-functioning pilot injection production line to Shenzhen Science and Technology Review Management Center for free to support Shenzhen Municipal Science and Technology Center incubator review management, support and service the local bio-pharmaceutical companies, big boost industrial development and upgrading of Shenzhen Bay innovation .
-
Shanghai Pharmaceuticals: Application for clinical trial of SPH5030 tablets has been accepted
Time of Update: 2021-07-06
On May 14, Shanghai Pharmaceutical announced that the application for the clinical trial of SPH5030 tablets was accepted, and it was intended to be used for the treatment of advanced solid tumors .
-
Roche's new generation of anti-CD20 monoclonal antibody Jialuohua® was approved in China!
Time of Update: 2021-07-06
5 months, compared with the standard treatment regimen in the control group, the combination of otuzumab chemotherapy can significantly reduce the risk of progression/recurrence or death by 34%, and a progression-free survival period Prolonged (three-year PFS rate was 80.
-
Drug costs are too high!
Time of Update: 2021-07-06
The United Kingdom's Drug Cost and Efficacy Management Agency (NICE) has issued a draft guideline that does not recommend the use of Roche's risdiplam (marketed as Evrysdi) for patients with type 1, 2 and 3 SMA .
-
3M launched a new "instant sterilization wipes"
Time of Update: 2021-07-06
It uses a unique patented technology to instantly remove 99% of microorganisms on non-porous hard surfaces .
With 3M technology's new wipe cloth, customers can transform it into a powerful cleaning solution that removes various types of bacteria, viruses, spores and other microorganisms with only clean water .
-
Youzhiyou Bio-PD-L1/TGF-β double antibody Y101D was approved for clinical use
Time of Update: 2021-07-06
In order to allow more patients to respond to these immunotherapies, many trials are evaluating the development of combination therapies or bispecific antibodies that combine anti-PD-1 / PD-L1 with other targets .
-
AffaMed Therapeutics Announces Appointment of Vijay Karwal as Chief Financial Officer
Time of Update: 2021-07-06
Vijay Karwal said: “Since its establishment in 2019, AffaMed has successfully built a development platform that serves patients in Greater China and the world through innovative treatment methods and solutions .
-
Roche's world's first accelerator launched in Shanghai
Time of Update: 2021-07-06
Shen Hong, head of the Roche Shanghai Innovation Center, said: "Through the launch of the accelerator project, we will further deepen the exchanges and cooperation with Zhangjiang Group, Hillhouse Ventures, scientific research institutions, start-ups and other parties at home and abroad, and create a global influence.
